Biomarin Pharmaceutical Inc’s recent filing unveils that its GVP, Chief Accounting Officer Burkhart Erin unloaded Company’s shares for reported $0.11 million on May 20 ’25. In the deal valued at $59.31 per share,1,786 shares were sold. As a result of this transaction, Burkhart Erin now holds 14,173 shares worth roughly $0.78 million.
Then, Burkhart Erin bought 1,786 shares, generating $105,928 in total proceeds.
Before that, Hubbard Cristin sold 273 shares. Biomarin Pharmaceutical Inc shares valued at $17,723 were divested by the EVP, Chief Commercial Officer at a price of $64.92 per share. As a result of the transaction, Hubbard Cristin now holds 32,700 shares, worth roughly $1.8 million.
Oppenheimer upgraded its Biomarin Pharmaceutical Inc [BMRN] rating to an Outperform from a a Perform in a research note published recently. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in mid November with a ‘”an Outperform”‘ rating. William Blair also remained covering BMRN and has decreased its forecast on October 30, 2024 with a “Mkt perform” recommendation from previously “an Outperform” rating.
Price Performance Review of BMRN
On Tuesday, Biomarin Pharmaceutical Inc [NASDAQ:BMRN] saw its stock fall -2.20% to $55.00. Over the last five days, the stock has lost -4.31%. Biomarin Pharmaceutical Inc shares have fallen nearly -16.32% since the year began. Nevertheless, the stocks have fallen -34.71% over the past one year. While a 52-week high of $94.85 was reached on 03/07/25, a 52-week low of $52.93 was recorded on 04/09/25.
Levels Of Support And Resistance For BMRN Stock
The 24-hour chart illustrates a support level at 54.50, which if violated will result in even more drops to 54.00. On the upside, there is a resistance level at 55.89. A further resistance level may holdings at 56.78.
